- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07554677
Understanding the Feasibility of a Co-designed Pre-radiotherapy Exercise Programme - A Single-arm Study (PReFACe)
Feasibility of a Co-designed PRe-radiotherapy Exercise Programme for People With Stage I-III Non-small Cell Lung cAnCEr: A Single-centre, Single Arm Pilot Study
The goal of this clinical trial is to understand the feasibility of a co-designed, pre-radiotherapy exercise programme for people with stage I-III non-small cell lung cancer. This involves people with lung cancer engaging in 20 minutes exercises sessions performed within the radiotherapy department and immediately before each treatment at a personalised intensity.
The main questions it aims to answer are:
To understand the acceptability of the exercise programme through monitoring recruitment rates, attendance of the exercise sessions, and adherence to prescribed exercise intensities. Adverse events will also be monitored to understand programme safety.
Follow-up qualitative interviews will be conducted with participants, their family members, and health care professionals (HCP) to further explore the acceptability of the exercise programme.
In total, participants will be invited to perform twenty, supervised exercise sessions scheduled immediately before each treatment within the radiotherapy department. Each exercise session will be twenty minutes in duration and will be performed on a stationary exercise bike. Regarding exercise intensity, there are four levels which may be prescribed depending on people's exercise history, baseline exercise experience, and personal preference. Participants may progress or regress exercise intensity levels throughout the programme depending on their adherence and preference.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a sequential, mixed method feasibility study consisting of two phases:
Phase 1: Quantitative data collection (feasibility outcomes)
Phase 2: Qualitative data collection (semi-structured interviews)
The exercise programme used in this study was co-designed through a series of workshops and meetings involving individuals affected by lung cancer and healthcare professionals.
Eligible participants must be receiving a prescribed radiotherapy dose of 55 Gy delivered in twenty fractions only, administered once daily, five days per week, over a four-week period. Accordingly, participants will be prescribed a total of twenty exercise sessions, performed once daily and scheduled in alignment with their radiotherapy treatment sessions.
Exercise intensity is personalised and based on a submaximal exercise test conducted at the participant's baseline assessment. This test will be used to determine each participant's maximum heart rate, which will then be entered into the Karvonen formula (Karvonen et al., 1957) to calculate percentage heart rate reserve. This calculation will establish individual heart-rate ranges corresponding to light, moderate, and vigorous exercise intensities. Starting exercise intensity level (1-4) will be determined based on a baseline six-minute walking test, clinical frailty score, and participant preference.
The four levels of exercise intensity increase in difficulty, and incorporate various durations of light, moderate, or high intensity exercise, including:
- Level 1: 10-minute warm-up at light intensity continuous cycling followed by 10 minutes of moderate intensity continuous cycling
- Level 2: 5-minute warm-up at light intensity continuous cycling followed by 15 minutes of moderate intensity continuous cycling
- Level 3: 5-minute warm-up at light intensity continuous cycling, followed by 10 minutes of moderate intensity continuous cycling, and 5 minutes of 30-second-high intensity intervals
- Level 4: 5-minute warm-up at light intensity continuous cycling, followed by 5 minutes of 30-second-high intensity intervals, 5 minutes of moderate intensity continuous cycling, and 5 minutes of 30-second-high intensity intervals
All participants will wear a chest-strap heart-rate monitor during each exercise session to ensure they are exercising at the prescribed intensity. Session adherence will be defined as completion of at least 75% of the prescribed exercise duration (i.e. 15-minutes).
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Matthew Peter Beggs, MSc, BSc
- Phone Number: +44 7759264875.
- Email: mbeggs06@qub.ac.uk
Study Contact Backup
- Name: Gillian Dr Prue, PhD., HCPC, FHEA, MCSP
- Phone Number: +44 28 9097 2345
- Email: g.prue@qub.ac.uk
Study Locations
-
-
Antrim
-
Belfast, Antrim, United Kingdom, BT9 7JL
- Recruiting
- Northern Ireland Cancer Centre, City Hospital, BHSCT
-
Contact:
- Matthew Peter Beggs, MSc, BSc
- Phone Number: +44 7759264875
- Email: mbeggs06@qub.ac.uk
-
Principal Investigator:
- Cathryn Dr Crockett, Consultant Clinical Oncologist
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with clinically or histologically confirmed NSCLC stages 1-3.
- Planned to receive treatment with curative intention radiation as primary treatment.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- At least 18 years of age.
- Can understand and communicate in English.
- Deemed safe to participate in moderate-intensity exercise and for ECG monitored maximal fitness test through the completion of a medical clearance form by their treating physician.
- Able to provide written and informed consent.
Exclusion Criteria:
- Unstable or new angina (diagnosed within the previous month).
- Unstable or acute heart failure, cardiomyopathy, or other uncontrolled cardiac disease (as evidenced by symptomatic fluid retention, excessive breathlessness, rapid weight gain, swollen ankles or pitting oedema) within the previous 3 months.
- Presence of new or uncontrolled cardiac arrhythmias.
- Confirmed or suspected spinal cord compression.
- Uncontrolled diabetes (e.g. medication changed within 1 month, has had episodes of hypoglycaemia during the previous 2 weeks, or hyperglycaemia which does not decrease with exercise during the previous 2 weeks).
- Is receiving combination treatment with chemotherapy or immunotherapy.
- Current active secondary malignancy other than non-melanoma skin cancer.
- Has had orthopaedic surgery within the previous 3 months on weight-bearing bones.
- Chest pain while undertaking exercise or physical activity.
- No > Grade 2 peripheral neuropathy.
- Metastatic disease beyond localised metastatic involvement (e.g. bone or brain).
- Has discovered any abnormalities shown on the ECG monitored maximal fitness test which warrant early termination or contraindicate physical activity.
- People with living with a physical disability which would limit their ability to exercise safely on the stationary exercise bike used within this study.
- People who are non-English speakers.
People who are pregnant.
- Patient participation in other clinical research - As an additional consideration, patients will be excluded if they are currently enrolled in an alternative exercise or physical activity study, as this may impact outcomes in both studies. However, if they have been involved in research prior to this or are currently involved in research in an unrelated area we will not immediately exclude them from trial participation. Instead, the Doctor of Philosophy (PhD) candidate, Chief investigator, and Principal investigator will discuss their involvement to determine safe and appropriate enrolment.
- Physical disability - it is with regret that we will be limited in our capacity to offer alternative exercises to accommodate people with a physical disability. To elaborate, the Belfast City Hospitals (BCH) main gym is willing to lend a stationary exercise bike to the research team in support of this study. However, due to limitations on equipment availability in the trust, and limited funding/resources to purchase equipment, people who have a physical disability which limits their capacity to exercise safely on the stationary bike will be excluded from this study. In an ideal scenario, we would also have a recumbent stationary bike to support more people with physical disability get involved within this research.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Pre-Radiotherapy exercise arm
Participants within the experimental arm will participate in the co-designed, pre-radiotherapy exercise programme alongside treatment.
|
Participants will participate in twenty, supervised exercise sessions, performed within the radiotherapy department, immediately before treatment.
Each session has a 20 minute duration at one of four exercise intensity levels based on the participants baseline assessment results, and preferences.
Participants involved in this study will receive 55 Gray (Gy) of radiotherapy only, administered in twenty fractions as per standard treatment pathways within the trust
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Eligibility rates
Time Frame: Screening and enrolment
|
The percentage of eligible participants identified and approached through participant screening
|
Screening and enrolment
|
|
Exercise programme attendance
Time Frame: Weeks 4-8 (PReFACe exercise programme)
|
The total number of attended sessions by the total number provided
|
Weeks 4-8 (PReFACe exercise programme)
|
|
Adherence to the exercise programme
Time Frame: Weeks 4-8 (PReFACe exercise programme)
|
Monitoring the participants ability to complete the advised duration and intensity of exercise during each session (adherence is accepted if completed 75% of duration without intensity modification)
|
Weeks 4-8 (PReFACe exercise programme)
|
|
Recruitment rate
Time Frame: Screening and recruitment
|
The total number of potential participants who were approached and agreed to participate as a percentage of the total number who were approached
|
Screening and recruitment
|
|
Participant retention rates
Time Frame: Week 0 (baseline assessment) to week 8 (PReFACe exercise programme end and post-intervention assessment)
|
The number of participants available to provide outcomes at the post-intervention assessment as a percentage of the total number recruited.
|
Week 0 (baseline assessment) to week 8 (PReFACe exercise programme end and post-intervention assessment)
|
|
Adverse event Common Terminology Criteria for Adverse Events (CTCAE) v5
Time Frame: Week 0 (baseline assessment) to week 8 (PReFACe exercise programme end and post-intervention assessment)
|
Assess the tolerability and safety of the intervention, via recording of intervention-associated adverse events (AE). AEs will be graded according to CTCAE v.5 as:
|
Week 0 (baseline assessment) to week 8 (PReFACe exercise programme end and post-intervention assessment)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline in quality of life using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-items (EORTC QLQ-30)
Time Frame: Week 0 (baseline assessment) to week 8 (end of study assessment)
|
EORTC QLQ-30 is a reliable and validated, multidimensional quality-of-life questionnaire which is widely used in research for people with lung cancer. The QLQ-C30 is composed of both multi-item scales and single-item measures, including: Five functional scales:
Three symptoms' scales:
A Global health Status (QoL) Six single items:
All scales and single-item measures range in score from 0 to 100. High scale scores represent a higher response level, thus:
|
Week 0 (baseline assessment) to week 8 (end of study assessment)
|
|
Change from baseline in quality of life using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 13 (EORTC QLQ-LC13)
Time Frame: Week 0 (baseline assessment) to week 8 (end of study assessment)
|
EORTC QLQ-LC13 is a reliable and validated, multidimensional quality-of-life questionnaire which is widely used in research for people with lung cancer. The QLQ-LC13 incorporates one multi-item scale to assess dyspnoea, and a series of single items assessing:
All single-item measures range in score from 0 to 100 with high scale scores representing a higher response level, thus: - High symptom scale/ single item scores = higher symptom burden |
Week 0 (baseline assessment) to week 8 (end of study assessment)
|
|
Impact of exercise programmes effect on symptom burden: Pain likert Scale
Time Frame: Week 0 (baseline assessment) to week 8 (end of study assessment)
|
Understanding the impact of the exercise programme on symptom burden on participants experience of pain using a 1-10 likert scale:
|
Week 0 (baseline assessment) to week 8 (end of study assessment)
|
|
Impact of exercise programmes effect on symptom burden: Fatigue likert Scale
Time Frame: Week 0 (baseline assessment) to week 8 (end of study assessment)
|
Understanding the impact of the exercise programme on symptom burden on participants experience of fatigue using a 1-10 likert scale:
|
Week 0 (baseline assessment) to week 8 (end of study assessment)
|
|
Impact of exercise programmes effect on symptom burden: Modified Medical Research Council (MRC) dyspnoea scale
Time Frame: Week 0 (baseline assessment), daily through PReFACe exercise programme (weeks 4-8) and end of study assessment (week 8)
|
The modified MRC dyspnoea scale is a 5-point (0-4) questionnaire that assesses a patient's breathing difficulty, or dyspnoea, during activity. Higher scores correspond with more breathlessness etc:
|
Week 0 (baseline assessment), daily through PReFACe exercise programme (weeks 4-8) and end of study assessment (week 8)
|
|
To assess the accessibility, acceptability and experience of the exercise programme through semi-structured qualitative interviews
Time Frame: Weeks 8-14 post-intervention follow-up period
|
Conduct of post-intervention, semi-structured, qualitative interviews with the following groups:
A total of 15 participants (n=5 from each group) is deemed sufficient to achieve data saturation. Semi-structured interview schedules were pre-constructed for each group. Interview schedules consist of open-ended questions to explore the participants/experience of the exercise programme in their own words. No scales are used as a part of this outcome. |
Weeks 8-14 post-intervention follow-up period
|
|
Baseline compared to post-intervention changes in participant distress levels using the National Comprehensive Cancer Network (NCCN) Distress thermometer.
Time Frame: Baseline assessment (week 0), weekly throughout the PReFACe exercise programme (weeks 4-8) and at post-study assessment (week 8)
|
The distress thermometer is a valid, and accurate screening tool used to quickly monitor for patient's distress with advanced cancer. The thermometer uses a 0-10 scale to measure patient distress over the past week with 0 representing no distress and 10 representing extreme distress. The thermometer also features a "Problem List" (covering practical, family, emotional, spiritual, and physical issues) to pinpoint causes of distress for referral |
Baseline assessment (week 0), weekly throughout the PReFACe exercise programme (weeks 4-8) and at post-study assessment (week 8)
|
|
Change in baseline to post-intervention physical fitness: Six- minute walking test
Time Frame: Baseline assessment (week 0) and post-study assessment (week 8)
|
A well-documented, validated and standardised sub-maximal fitness test measuring the distance a person can walk on a flat, solid surface in six minutes. Participants walk back and forth along a measured track to measure total distance covered in meters within six minutes. Greater distance covered (meters) indicate greater baseline fitness. Greater post-test distance covered (meters) than baseline scores indicate improvements in basic mobility. Reduced post-test distance covered (meters) than baseline scores indicate reductions in basic mobility. |
Baseline assessment (week 0) and post-study assessment (week 8)
|
|
Change in baseline to post-intervention physical fitness: 30-second sit-to-stand
Time Frame: Baseline assessment (week 0) and post-study assessment (week 8)
|
A well-documented, validated, and standardised test to measure functional lower extremity strength.
Participants perform as many sit-to-stand reps as they can within 30 seconds.
|
Baseline assessment (week 0) and post-study assessment (week 8)
|
|
Change in baseline to post-intervention physical functioning: Rockwood Clinical Frailty Scale (CFS)
Time Frame: Baseline assessment (week 0) and post-study assessment (week 8)
|
The Rockwood CFS is used as a valid assessment tool for screening frailty in older adults. This is a 1-9 scale, with higher scores indicating greater frailty:
|
Baseline assessment (week 0) and post-study assessment (week 8)
|
|
Change in baseline to post-intervention physical activity: The International Physical Activity Questionnaire - Short Form (IPAQ-SF)
Time Frame: Baseline assessment (week 0) and post-study assessment (week 8)
|
The IPAQ-SF will be used to explore the influence of the pre-radiotherapy exercise programme on the participant's weekly physical activity levels pre- and post-study. Based on results, physical activity levels based on scores can be calculated as:
|
Baseline assessment (week 0) and post-study assessment (week 8)
|
|
Change in baseline to post-intervention physical activity: Huffman Exercise Satisfactions Scale
Time Frame: Baseline assessment (week 0) and post-study assessment (week 8)
|
The Huffman Exercise Satisfaction Scale was developed with stakeholders as a novel approach to measure older adults (aged ≥55 years) satisfaction with their physical activity levels. There questionnaire measures two scales:
Mean scores are taken from each scale to total participants exercise enjoyment and satisfaction. |
Baseline assessment (week 0) and post-study assessment (week 8)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011 Apr 23;6:42. doi: 10.1186/1748-5908-6-42.
- Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, Mitnitski A. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005 Aug 30;173(5):489-95. doi: 10.1503/cmaj.050051.
- Skivington K, Matthews L, Simpson SA, Craig P, Baird J, Blazeby JM, Boyd KA, Craig N, French DP, McIntosh E, Petticrew M, Rycroft-Malone J, White M, Moore L. A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance. BMJ. 2021 Sep 30;374:n2061. doi: 10.1136/bmj.n2061.
- Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer. 1994;30A(5):635-42. doi: 10.1016/0959-8049(94)90535-5.
- Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. doi: 10.1093/jnci/85.5.365.
- Lee PH, Macfarlane DJ, Lam TH, Stewart SM. Validity of the International Physical Activity Questionnaire Short Form (IPAQ-SF): a systematic review. Int J Behav Nutr Phys Act. 2011 Oct 21;8:115. doi: 10.1186/1479-5868-8-115.
- KARVONEN MJ, KENTALA E, MUSTALA O. The effects of training on heart rate; a longitudinal study. Ann Med Exp Biol Fenn. 1957;35(3):307-15. No abstract available.
- Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer. 1995 Jun;12(3):199-220. doi: 10.1016/0169-5002(95)00450-f.
- Peddle-McIntyre CJ, Singh F, Thomas R, Newton RU, Galvao DA, Cavalheri V. Exercise training for advanced lung cancer. Cochrane Database Syst Rev. 2019 Feb 11;2(2):CD012685. doi: 10.1002/14651858.CD012685.pub2.
- Sasso JP, Eves ND, Christensen JF, Koelwyn GJ, Scott J, Jones LW. A framework for prescription in exercise-oncology research. J Cachexia Sarcopenia Muscle. 2015 Jun;6(2):115-24. doi: 10.1002/jcsm.12042. Epub 2015 May 11.
- Campbell KL, Winters-Stone KM, Wiskemann J, May AM, Schwartz AL, Courneya KS, Zucker DS, Matthews CE, Ligibel JA, Gerber LH, Morris GS, Patel AV, Hue TF, Perna FM, Schmitz KH. Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable. Med Sci Sports Exerc. 2019 Nov;51(11):2375-2390. doi: 10.1249/MSS.0000000000002116.
- Cormie P, Zopf EM, Zhang X, Schmitz KH. The Impact of Exercise on Cancer Mortality, Recurrence, and Treatment-Related Adverse Effects. Epidemiol Rev. 2017 Jan 1;39(1):71-92. doi: 10.1093/epirev/mxx007.
- Pearson N, Naylor PJ, Ashe MC, Fernandez M, Yoong SL, Wolfenden L. Guidance for conducting feasibility and pilot studies for implementation trials. Pilot Feasibility Stud. 2020 Oct 31;6(1):167. doi: 10.1186/s40814-020-00634-w.
- Avancini A, Sartori G, Gkountakos A, Casali M, Trestini I, Tregnago D, Bria E, Jones LW, Milella M, Lanza M, Pilotto S. Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled? Oncologist. 2020 Mar;25(3):e555-e569. doi: 10.1634/theoncologist.2019-0463. Epub 2019 Nov 26.
- Totton N, Lin J, Julious S, Chowdhury M, Brand A. A review of sample sizes for UK pilot and feasibility studies on the ISRCTN registry from 2013 to 2020. Pilot Feasibility Stud. 2023 Nov 21;9(1):188. doi: 10.1186/s40814-023-01416-w.
- Church S, Rogers E, Rockwood K, Theou O. A scoping review of the Clinical Frailty Scale. BMC Geriatr. 2020 Oct 7;20(1):393. doi: 10.1186/s12877-020-01801-7.
- Viamonte SG, Joaquim AV, Alves AJ, Vilela E, Capela A, Ferreira C, Duarte BF, Rato ND, Teixeira MP, Tavares A, Santos M, Ribeiro F. Cardio-Oncology Rehabilitation for Cancer Survivors With High Cardiovascular Risk: A Randomized Clinical Trial. JAMA Cardiol. 2023 Dec 1;8(12):1119-1128. doi: 10.1001/jamacardio.2023.3558.
- Ziolkowska-Suchanek I. Mimicking Tumor Hypoxia in Non-Small Cell Lung Cancer Employing Three-Dimensional In Vitro Models. Cells. 2021 Jan 12;10(1):141. doi: 10.3390/cells10010141.
- Seet-Lee C, Yee J, Morahan H, Ross LS, Edwards KM. The effect of aerobic exercise on tumour blood delivery: a systematic review and meta-analysis. Support Care Cancer. 2022 Nov;30(11):8637-8653. doi: 10.1007/s00520-022-07132-0. Epub 2022 Jun 2.
- World Health Organization (2023) Lung Cancer
- World Health Organization (2018) More active people for a healthier world
- Williams, N. (2017) 'The Borg Rating of Perceived Exertion (RPE) scale ', Occupational Medicine, 67 (5), pp. 404-405.
- United Kingdom Lung Cancer Coalition (2024) Driving Quality Improvements in UK Lung Cancer: Utilising good practice and innovation to deliver optimal care and outcomes
- Tran DL, Kamaladasa Y, Munoz PA, Kotchetkova I, D'Souza M, Celermajer DS, Maiorana A, Cordina R. Estimating exercise intensity using heart rate in adolescents and adults with congenital heart disease: Are established methods valid? Int J Cardiol Congenit Heart Dis. 2022 Mar 26;8:100362. doi: 10.1016/j.ijcchd.2022.100362. eCollection 2022 Jun.
- Toohey K, Mizrahi D, Hart NH, Singh B, Lopez P, Hunter M, Newton RU, Schmitz KH, Adams D, Edbrooke L, Hayes S. Exercise in cancer care for people with lung cancer: A narrative synthesis. J Sci Med Sport. 2025 Jan;28(1):16-25. doi: 10.1016/j.jsams.2024.08.002. Epub 2024 Aug 8.
- Tivey A, Ullah M, Beech A, Ng C, Cove-Smith L. Can frailty screening tools predict completion of chemotherapy and chemotherapy toxicity in patients with thoracic malignancy? J Geriatr Oncol. 2020 Sep;11(7):1154-1156. doi: 10.1016/j.jgo.2020.03.002. Epub 2020 Mar 11. No abstract available.
- Suveg K, Plasswilm L, Iseli T, Leskow P, Fischer GF, Putora PM. Role of Adjuvant Radiotherapy in Non-Small Cell Lung Cancer-A Review. Cancers (Basel). 2022 Mar 23;14(7):1617. doi: 10.3390/cancers14071617.
- Sia J, Szmyd R, Hau E, Gee HE. Molecular Mechanisms of Radiation-Induced Cancer Cell Death: A Primer. Front Cell Dev Biol. 2020 Feb 13;8:41. doi: 10.3389/fcell.2020.00041. eCollection 2020.
- Riba MB, Donovan KA, Ahmed K, Andersen B, Braun I, Breitbart WS, Brewer BW, Corbett C, Fann J, Fleishman S, Garcia S, Greenberg DB, Handzo GF, Hoofring LH, Huang CH, Hutchinson S, Johns S, Keller J, Kumar P, Lahijani S, Martin S, Niazi SK, Pailler M, Parnes F, Rao V, Salman J, Scher E, Schuster J, Teply M, Usher A, Valentine AD, Vanderlan J, Lyons MS, McMillian NR, Darlow SD. NCCN Guidelines(R) Insights: Distress Management, Version 2.2023. J Natl Compr Canc Netw. 2023 May;21(5):450-457. doi: 10.6004/jnccn.2023.0026.
- Piraux E, Caty G, Aboubakar Nana F, Reychler G. Effects of exercise therapy in cancer patients undergoing radiotherapy treatment: a narrative review. SAGE Open Med. 2020 Jun 17;8:2050312120922657. doi: 10.1177/2050312120922657. eCollection 2020.
- Pinto BM, Ciccolo JT. Physical activity motivation and cancer survivorship. Recent Results Cancer Res. 2011;186:367-87. doi: 10.1007/978-3-642-04231-7_16.
- Penko AL, Barkley JE, Koop MM, Alberts JL. Borg scale is valid for ratings of perceived exertion for individuals with Parkinson's disease. Int J Exerc Sci. 2017 Jan 1;10(1):76-86. doi: 10.70252/RVAQ3828. eCollection 2017.
- Ortmann BM. Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunity. BMJ Oncol. 2024 Feb 1;3(1):e000154. doi: 10.1136/bmjonc-2023-000154. eCollection 2024.
- Norton K, Norton L, Sadgrove D. Position statement on physical activity and exercise intensity terminology. J Sci Med Sport. 2010 Sep;13(5):496-502. doi: 10.1016/j.jsams.2009.09.008. Epub 2009 Dec 10.
- Nisar H, Sanchidrian Gonzalez PM, Brauny M, Labonte FM, Schmitz C, Roggan MD, Konda B, Hellweg CE. Hypoxia Changes Energy Metabolism and Growth Rate in Non-Small Cell Lung Cancer Cells. Cancers (Basel). 2023 Apr 26;15(9):2472. doi: 10.3390/cancers15092472.
- Nikitara K, Odani S, Demenagas N, Rachiotis G, Symvoulakis E, Vardavas C. Prevalence and correlates of physical inactivity in adults across 28 European countries. Eur J Public Health. 2021 Oct 11;31(4):840-845. doi: 10.1093/eurpub/ckab067.
- National Institute of Health, (2021). Common Terminology Criteria for Adverse Events (CTCAE)
- National Institute for Health and Care Excellence (2014) Behaviour Change: Individual Approaches
- National Data Guardian (2020) The Eight Caldicott Principles.
- Muz B, de la Puente P, Azab F, Azab AK. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl). 2015 Dec 11;3:83-92. doi: 10.2147/HP.S93413. eCollection 2015.
- Morgan B, Hejdenberg J, Kuleszewicz K, Armstrong D, Ziebland S. Are some feasibility studies more feasible than others? A review of the outcomes of feasibility studies on the ISRCTN registry. Pilot Feasibility Stud. 2021 Nov 8;7(1):195. doi: 10.1186/s40814-021-00931-y.
- Moreton, R., Stutz, A., Robinson, S., Mulla, I., Winter, M., Roberts, J. & Hillsdon, M. (2018) Evaluation of the Macmillan Physical Activity Behaviour Change Care Pathway
- Moreno-Arino M, Torrente Jimenez I, Cartanya Gutierrez A, Oliva Morera JC, Comet R. Assessing the strengths and weaknesses of the Clinical Frailty Scale through correlation with a frailty index. Aging Clin Exp Res. 2020 Nov;32(11):2225-2232. doi: 10.1007/s40520-019-01450-w. Epub 2020 Jan 2.
- McCullough DJ, Stabley JN, Siemann DW, Behnke BJ. Modulation of blood flow, hypoxia, and vascular function in orthotopic prostate tumors during exercise. J Natl Cancer Inst. 2014 Apr;106(4):dju036. doi: 10.1093/jnci/dju036. Epub 2014 Mar 13.
- Macmillan (2023) Physical Activity and Cancer
- Lumivero (2017) NVivo (Version 12).
- Ligibel JA, Bohlke K, Alfano CM. Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline Summary and Q&A. JCO Oncol Pract. 2022 Oct;18(10):695-697. doi: 10.1200/OP.22.00277. Epub 2022 Jul 5. No abstract available.
- Liu Y, Wu W, Cai C, Zhang H, Shen H, Han Y. Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduct Target Ther. 2023 Apr 12;8(1):160. doi: 10.1038/s41392-023-01419-2.
- Koller M, Musoro JZ, Tomaszewski K, Coens C, King MT, Sprangers MAG, Groenvold M, Cocks K, Velikova G, Flechtner HH, Bottomley A. Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma - Interpretation guidance derived from two randomized EORTC trials. Lung Cancer. 2022 May;167:65-72. doi: 10.1016/j.lungcan.2022.03.018. Epub 2022 Mar 29.
- Kirkham AA, Campbell KL, McKenzie DC. Comparison of aerobic exercise intensity prescription methods in breast cancer. Med Sci Sports Exerc. 2013 Aug;45(8):1443-50. doi: 10.1249/MSS.0b013e3182895195.
- Kilari D, Soto-Perez-de-Celis E, Mohile SG, Alibhai SM, Presley CJ, Wildes TM, Klepin HD, Demark-Wahnefried W, Jatoi A, Harrison R, Won E, Mustian KM. Designing exercise clinical trials for older adults with cancer: Recommendations from 2015 Cancer and Aging Research Group NCI U13 Meeting. J Geriatr Oncol. 2016 Jul;7(4):293-304. doi: 10.1016/j.jgo.2016.04.007. Epub 2016 May 31.
- Kallio H, Pietila AM, Johnson M, Kangasniemi M. Systematic methodological review: developing a framework for a qualitative semi-structured interview guide. J Adv Nurs. 2016 Dec;72(12):2954-2965. doi: 10.1111/jan.13031. Epub 2016 Jun 23.
- Huffman MK, Christ SL, Ferraro KF, Klenosky DB, Marceau K, Amireault S. Questions to Measure Enjoyment of and Satisfaction With Physical Activity: Are They Appropriate for Use in an Older Population? Innov Aging. 2021 Oct 4;5(4):igab041. doi: 10.1093/geroni/igab041. eCollection 2021.
- Hircock C, Wang AJ, Goonaratne E, Sferrazza D, Bottomley A, Cella D, Lee SF, Chan AW, Chow E, Wong HCY. Comparing the EORTC QLQ-LC13, EORTC QLQ-LC29, and the FACT-L for assessment of quality of life in patients with lung cancer - an updated systematic review. Curr Opin Support Palliat Care. 2024 Dec 1;18(4):260-268. doi: 10.1097/SPC.0000000000000725. Epub 2024 Oct 30.
- Graham-Wisener L, Dempster M, Sadler A, McCann L, McCorry NK. Validation of the Distress Thermometer in patients with advanced cancer receiving specialist palliative care in a hospice setting. Palliat Med. 2021 Jan;35(1):120-129. doi: 10.1177/0269216320954339. Epub 2020 Sep 11.
- Esteves M, Monteiro MP, Duarte JA. The Effects of Physical Exercise on Tumor Vasculature: Systematic Review and Meta-analysis. Int J Sports Med. 2021 Dec;42(14):1237-1249. doi: 10.1055/a-1533-1876. Epub 2021 Aug 2.
- Egegaard T, Rohold J, Lillelund C, Persson G, Quist M. Pre-radiotherapy daily exercise training in non-small cell lung cancer: A feasibility study. Rep Pract Oncol Radiother. 2019 Jul-Aug;24(4):375-382. doi: 10.1016/j.rpor.2019.06.003. Epub 2019 Jun 21.
- Dufresne S, Gueritat J, Chiavassa S, Noblet C, Assi M, Rioux-Leclercq N, Rannou-Bekono F, Lefeuvre-Orfila L, Paris F, Rebillard A. Exercise training improves radiotherapy efficiency in a murine model of prostate cancer. FASEB J. 2020 Apr;34(4):4984-4996. doi: 10.1096/fj.201901728R. Epub 2020 Feb 11.
- Coletta AM, Basen-Engquist KM, Schmitz KH. Exercise Across the Cancer Care Continuum: Why It Matters, How to Implement It, and Motivating Patients to Move. Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-7. doi: 10.1200/EDBK_349635.
- Cleland BT, Ingraham BA, Pitluck MC, Woo D, Ng AV. Reliability and Validity of Ratings of Perceived Exertion in Persons With Multiple Sclerosis. Arch Phys Med Rehabil. 2016 Jun;97(6):974-82. doi: 10.1016/j.apmr.2016.01.013. Epub 2016 Feb 1.
- Brown M, Rebillard A, Hart NH, O'Connor D, Prue G, O'Sullivan JM, Jain S. Modulating Tumour Hypoxia in Prostate Cancer Through Exercise: The Impact of Redox Signalling on Radiosensitivity. Sports Med Open. 2022 Apr 8;8(1):48. doi: 10.1186/s40798-022-00436-9.
- Bradley, P., Merchant, Z., Rowlinson-Groves, K., Grundy, S., Al-Najjar, H., Brown, L., Dand, A., Farran, C., Bayman, N., Banfill, K., Wray, D., Moore, J. & Evison, M. (2021) 'P212 Prehab4Cancer: an innovative regional lung cancer prehabilitation service', Thorax, 76 (1), pp. A204-A205
- Beale, L., Carter, H., Doust, J., Brickley, G., Silberbauer, J. & Llyod, G. (2010) 'Exercise heart rate guidelines overestimate recommended intensity for chronic heart failure patients', British Journal of Cardiology, 17, pp.133-137.
- Barker HE, Paget JT, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015 Jul;15(7):409-25. doi: 10.1038/nrc3958.
- Balachandran AT, Vigotsky AD, Quiles N, Mokkink LB, Belio MA, Glenn JM. Validity, reliability, and measurement error of a sit-to-stand power test in older adults: A pre-registered study. Exp Gerontol. 2021 Mar;145:111202. doi: 10.1016/j.exger.2020.111202. Epub 2020 Dec 19.
- Atun R, Jaffray DA, Barton MB, Bray F, Baumann M, Vikram B, Hanna TP, Knaul FM, Lievens Y, Lui TY, Milosevic M, O'Sullivan B, Rodin DL, Rosenblatt E, Van Dyk J, Yap ML, Zubizarreta E, Gospodarowicz M. Expanding global access to radiotherapy. Lancet Oncol. 2015 Sep;16(10):1153-86. doi: 10.1016/S1470-2045(15)00222-3.
- Association of Chartered Physiotherapists in Cardiovascular Rehabilitation (2023) Standards for Physical Activity and Exercise in the Cardiovascular Population: 4th Edition
- Vinod SK, Hau E. Radiotherapy treatment for lung cancer: Current status and future directions. Respirology. 2020 Nov;25 Suppl 2:61-71. doi: 10.1111/resp.13870. Epub 2020 Jun 9.
- Varkey B. Principles of Clinical Ethics and Their Application to Practice. Med Princ Pract. 2021;30(1):17-28. doi: 10.1159/000509119. Epub 2020 Jun 4.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Respiratory Tract Diseases
- Lung Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Behavior
- Lung Neoplasms
- Motor Activity
- Motor Activity
- Movement
- Musculoskeletal Physiological Phenomena
- Musculoskeletal and Neural Physiological Phenomena
- Therapeutics
- Exercise
- Radiotherapy
Other Study ID Numbers
- 350051
- 25017GP-SS (Other Identifier: Belfast Health and Social Care Trust reference)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer
-
M.D. Anderson Cancer CenterRecruitingStage III Lung Cancer AJCC v8 | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingStage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
Beth Israel Deaconess Medical CenterDana-Farber Cancer Institute; MedWaves, IncRecruitingLung Cancer | Lung Cancer Stage I | Lung Cancer Stage II | Stage I Lung Cancer | Stage I - II Primary Lung Cancer | Stage II Lung CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer... and other conditionsUnited States
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingCaregiver | Stage III Lung Cancer AJCC v7 | Stage I Lung Cancer AJCC v7 | Stage II Lung Cancer AJCC v7 | Stage IB Lung Cancer AJCC v7 | Stage IA Lung Cancer AJCC v7 | Stage IIA Lung Cancer AJCC v7 | Stage IIB Lung Cancer AJCC v7 | Stage IIIA Lung Cancer AJCC v7 | Stage IIIB Lung Cancer AJCC v7United States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)TerminatedStage IV Lung Cancer | Stage III Lung Cancer | Stage I Lung Cancer | Stage II Lung CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Genentech, Inc.Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditionsUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
University of California, San FranciscoMerck Sharp & Dohme LLCWithdrawnLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
Clinical Trials on Exercise
-
National Institute of Neurological Disorders and...TerminatedTraumatic Brain InjuryUnited States
-
University of Texas, El PasoRecruitingKnee Osteoarthritis | Knee Pain Chronic | Central Pain SyndromeUnited States
-
Aksaray University Training and Research HospitalCompletedExercise Training | Lactate Blood Increase | Cognitive Functions | BDNFTurkey (Türkiye)
-
Toronto Rehabilitation InstituteCompletedAcute Myeloid LeukemiaCanada
-
Bayero University Kano, NigeriaCompletedChronic Low Back PainNigeria
-
University of Alabama at BirminghamCompletedCystic FibrosisUnited States
-
University College CorkRecruitingDepressive Disorder, MajorIreland
-
Sahmyook UniversityRecruitingChronic Nonspecific Neck PainKorea, Republic of
-
Uskudar UniversityCompleted
-
Yuksek Ihtisas UniversityCompletedDementia | Frailty | Cognitive Function | Reaction Time | Aerobic Exercise | Balance ExerciseTurkey